Classification of the present pharmaceutical agents based on the possible effective mechanism on the COVID-19 infection

被引:12
作者
Pouya, Maryam Amini [1 ]
Afshani, Seyyedeh Maryam [2 ]
Maghsoudi, Armin Salek [3 ]
Hassani, Shokoufeh [3 ,4 ]
Mirnia, Kayvan [5 ]
机构
[1] Univ Tehran Med Sci, Sch Pharm, Dept Pharmaceut, Tehran, Iran
[2] Univ Tehran Med Sci, Sch Pharm, Dept Pharmacoecon, Tehran, Iran
[3] Univ Tehran Med Sci, Sch Pharm, Dept Toxicol & Pharmacol, Tehran, Iran
[4] Univ Tehran Med Sci, Pharmaceut Sci Res Ctr PSRC, Inst Pharmaceut Sci TIPS, Toxicol & Dis Grp TDG, Tehran, Iran
[5] Univ Tehran Med Sci, Childrens Med Ctr, Tehran, Iran
关键词
Coronaviruses; COVID-19; SARS-CoV-2; Pandemic; Pharmaceutical agents; Possible treatments; Drug classification; CONVALESCENT PLASMA; CORONAVIRUS; ENTRY; SARS-COV-2; PROTEASE; TMPRSS2; VIRUS; SARS; POLYMORPHISM; PROTEOLYSIS;
D O I
10.1007/s40199-020-00359-4
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objectives There are several types of research on the COVID-19 disease which have been conducting. It seems that prevailing over the pandemic would be achieved only by mastering over the virus pathophysiology. We tried to categorize the massive amount of available information for useful interpretation. Evidence acquisition We searched databases with different keywords and search strategies that focus on virulence and pathophysiology of COVID-19. The present review has aimed to gather and categorize all implemented drugs based on the susceptible virulence mechanisms, and the pathophysiological events in the host cells, discussing and suggesting treatments. Results As a result, the COVID-19 lifecycle were categorized as following steps: "Host Cell Attachment" which is mainly conducted with ACE(2)receptors and TMPRSS2 from the host cell and Spike (S) protein, "Endocytosis Pathway" which is performed mainly by clathrin-mediated endocytosis, and "Viral Replication" which contains translation and replication of RNA viral genome. The virus pathogenicity is continued by "Inflammatory Reactions" which mainly caused moderate to severe COVID-19 disease. Besides, the possible effective therapeutics' mechanism and the pharmaceutical agents that had at least one experience as a preclinical or clinical study on COVID-19 were clearly defined. Conclusion The treatment protocol would be occasional based on the stage of the infection and the patient situation. The cocktail of medicines, which could affect almost all mentioned stages of COVID-19 disease, might be vital for patients with severe phenomena.
引用
收藏
页码:745 / 764
页数:20
相关论文
共 165 条
[1]  
Abrahams L., 2020, COVID 19 ACQUIRED AC
[2]  
Ahmed T, 2019, LINKED PNEUMONIA CHI
[3]  
Ai T, 2020, RADIOLOGY
[4]   Competitive Fitness in Coronaviruses Is Not Correlated with Size or Number of Double-Membrane Vesicles under Reduced-Temperature Growth Conditions [J].
Al-Mulla, Hawaa M. N. ;
Turrell, Lauren ;
Smith, Nicola M. ;
Payne, Luke ;
Baliji, Surendranath ;
Zuest, Roland ;
Thiel, Volker ;
Baker, Susan C. ;
Siddell, Stuart G. ;
Neuman, Benjamin W. .
MBIO, 2014, 5 (02)
[5]   Blockade of SARS-CoV-2 infection by recombinant soluble ACE2 [J].
Alhenc-Gelas, Francois ;
Drueke, Tilman B. .
KIDNEY INTERNATIONAL, 2020, 97 (06) :1091-1093
[6]   Chloroquine and COVID-19: A Light at the End of the Tunnel, or is it Another Train? [J].
Aljofan, Mohamad ;
Gaipov, Abduzhappar .
ELECTRONIC JOURNAL OF GENERAL MEDICINE, 2020, 17 (04)
[7]  
Anastasopoulou S, 2020, BIOL SARS COV 2 ENSU
[8]   The proximal origin of SARS-CoV-2 [J].
Andersen, Kristian G. ;
Rambaut, Andrew ;
Lipkin, W. Ian ;
Holmes, Edward C. ;
Garry, Robert F. .
NATURE MEDICINE, 2020, 26 (04) :450-452
[9]  
[Anonymous], 2020, COR DIS 2019 COVID 1
[10]  
Bao L., 2020, PATHOGENICITY SARS C